Literature DB >> 12559327

Complex visual hallucinations in the visually impaired: the Charles Bonnet Syndrome.

G Jayakrishna Menon1, Imran Rahman, Sharmila J Menon, Gordon N Dutton.   

Abstract

Visually impaired patients may experience complex visual hallucinations, a condition known as the Charles Bonnet Syndrome. Patients usually possess insight into the unreality of their visual experiences, which are commonly pleasant but may sometimes cause distress. The hallucinations consist of well-defined, organized, and clear images over which the subject has little control. It is believed that they represent release phenomena due to de-afferentation of the visual association areas of the cerebral cortex, leading to a form of phantom vision. Cognitive defects, social isolation, and sensory deprivation have also been implicated in the etiology of this condition. This condition, which is most common in the elderly, frequently goes unrecognized in clinical practice, due to both lack of awareness among doctors and patients' reluctance to admit to hallucinatory experiences, for fear of being labeled mentally unstable. Furthermore, patients who comprehend the unreality of their hallucinations may be distressed by the real fear of imminent insanity. Sensitive and sympathetic history taking is essential to ascertain the existence of hallucinations. Reassurance and explanation that the visions are benign and do not signify mental illness have a powerful therapeutic effect. Hallucinatory activity may terminate spontaneously, on improving visual function or on addressing social isolation. There is no universally effective drug treatment but anticonvulsants may play a limited role in aborting the hallucinations. Physician awareness and empathy are the cornerstones of management.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12559327     DOI: 10.1016/s0039-6257(02)00414-9

Source DB:  PubMed          Journal:  Surv Ophthalmol        ISSN: 0039-6257            Impact factor:   6.048


  69 in total

1.  Charles Bonnet syndrome--elderly people and visual hallucinations.

Authors:  Anu Jacob; Sanjeev Prasad; Mike Boggild; Sanjeev Chandratre
Journal:  BMJ       Date:  2004-06-26

2.  Charles Bonnet syndrome and brimonidine: comments.

Authors:  I Rahman; B Fernando; M Harrison
Journal:  Br J Ophthalmol       Date:  2004-05       Impact factor: 4.638

3.  Ophthaproblem. Charles Bonnet's syndrome.

Authors:  Jason Blair; Sanjay Sharma
Journal:  Can Fam Physician       Date:  2004-10       Impact factor: 3.275

4.  Charles Bonnet syndrome in patients with glaucoma and good acuity.

Authors:  S A Madill; D H Ffytche
Journal:  Br J Ophthalmol       Date:  2005-06       Impact factor: 4.638

5.  Musical hallucinations in a musician.

Authors:  J D Warren; G D Schott
Journal:  J Neurol       Date:  2006-04-10       Impact factor: 4.849

6.  Visual hallucinations following stellate ganglion block in a patient with central retinal artery occlusion.

Authors:  Takuji Kurimoto; Masashi Takata; Masashi Nishimura; Yuichi Tagami; Norio Okamoto; Osamu Mimura
Journal:  Jpn J Ophthalmol       Date:  2006 Nov-Dec       Impact factor: 2.447

7.  Visual hallucinations: differential diagnosis and treatment.

Authors:  Ryan C Teeple; Jason P Caplan; Theodore A Stern
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2009

Review 8.  Charles Bonnet syndrome: two case reports and review of the literature.

Authors:  Alberto Lerario; Andrea Ciammola; Barbara Poletti; Floriano Girotti; Vincenzo Silani
Journal:  J Neurol       Date:  2013-02-05       Impact factor: 4.849

9.  Charles Bonnet Syndrome Following Trans-Sphenoidal Adenomectomy without Optic Nerve Atrophy.

Authors:  Jang-Ho Park; Joon-Ho Ahn; Jun-Bum Park; Soohyun Joe
Journal:  Psychiatry Investig       Date:  2016-09-30       Impact factor: 2.505

10.  Hallucinations in visually impaired individuals: an analysis of the National Comorbidity Survey Replication.

Authors:  Yoshihiro Kinoshita; Masao Tsuchiya; Norito Kawakami; Toshi A Furukawa; David Kingdon
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2008-07-26       Impact factor: 4.328

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.